Research Article

Integrated Analysis Identifies an Immune-Based Prognostic Signature for the Mesenchymal Identity in Gastric Cancer

Table 1

Patients’ characteristics in public datasets.

Training cohortValidation cohorts
GSE15459 ()GSE13861 ()GSE84437 ()GSE62254 ()GSE26901 ()GSE29272 ()

Age (years)64 (23-92)61 (32-83)60 (27-86)62 (24-86)56 (28-74)56 (23-73)
Gender
 Female67 (35%)19 (29%)137 (32%)101 (34%)37 (38%)31 (23%)
 Male125 (65%)46 (71%)296 (68%)199 (66%)60 (62%)103 (77%)
Histology
 Diffuse75 (39%)30 (46%)135 (45%)10 (10%)
 Indeterminate2 (1%)
 Intestinal99 (52%)19 (29%)146 (49%)71 (73%)
 Mixed18 (9%)12 (18%)17 (6%)5 (5%)
 Unknown4 (6%)11 (11%)
Site
 Antrum26 (40%)152 (51%)51 (53%)
 Body31 (48%)110 (37%)30 (31%)
 Cardia4 (6%)32 (11%)
 Entire1 (2%)3 (1%)4 (4%)
 Fundus1 (2%)12 (12%)
 Unknown2 (3%)
Stage
 I31 (16%)12 (18%)31 (10%)33 (34%)5 (4%)
 II29 (15%)12 (18%)97 (32%)17 (18%)5 (4%)
 III72 (38%)25 (38%)95 (32%)32 (33%)115 (86%)
 IV60 (31%)16 (25%)77 (26%)15 (15%)9 (7%)